The effect of multiple doses of ubrogepant on the pharmacokinetics of an oral contraceptive in healthy women: Results of an open-label, single-center, two-period, fixed-sequence study

The effect of multiple doses of ubrogepant on the pharmacokinetics of an oral contraceptive in healthy women: Results of an open-label, single-center, two-period, fixed-sequence study

Background: Ubrogepant is a novel, oral calcitonin gene–related peptide receptor antagonist for acute treatment of migraine. This study evaluated potential drug–drug interactions between ubrogepant and an oral contraceptive containing ethinyl estradiol (EE) and norgestimate (NGM). Methods: This open...

Full description

Bibliographic Details
Main Authors: Chi-Chung Li, John Palcza, Jialin Xu, Bob Thornton, Wendy Ankrom, Abhijeet Jakate, Eugene E Marcantonio
Format: Article
Language:English
Published: SAGE Publishing 2020-02-01
Series:Cephalalgia Reports
Online Access:https://doi.org/10.1177/2515816320905082

Internet

https://doi.org/10.1177/2515816320905082

Similar Items